53865-58-0

Upstream product

• 98-95-3 nitrobenzene 
• 1384477-13-7 methyl 4-[(1H-imidazol-1-ylcarbonyl)amino]benzoate 
• 62-53-3 aniline 
• 103-71-9 phenyl isocyanate 
• 619-45-4 4-methoxycarbonyl aniline 

Relevant academic research and scientific papers

Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors

Histone deacetylases (HDACs) are a family of enzymes that modulate the acetylation status histones and non-histone proteins. Histone deacetylase inhibitors (HDACis) have emerged as an alternative therapeutic approach for the treatment of several malignanc

Polystyrene anchored ruthenium(II) complex catalyzed carbonylation of nitrobenzene and amines for the synthesis of disubstituted ureas

The catalytically active complex [Ru(PS-imd)(CO)2Cl2] (PS-imd = polystyrene anchored imidazole) was synthesized and characterized using various spectroscopic techniques. The complex is well characterized and highly stable. The catalytic activity of the resulting species was investigated towards the synthesis of diphenyl urea and other disubstituted ureas. The experiments were carried out under high CO pressure, high temperature condition in mild coordinating media. The catalyst was found to produce excellent yields with high product selectivity. Variable yields are obtained depending on the substituent on nitrobenzene and aniline. The effects of co-solvent and co-catalyst were also studied. The catalyst was very stable and could be reused for more than five times without any noticeable loss of its catalytic activity.

Synthesis of unsymmetrical biaryl ureas from N-carbamoylimidazoles: Kinetics and application

N-Carbamoylimidazoles dissociate in solution to yield imidazole and an isocyanate that may be reacted with another aryl amine to form an unsymmetrical biaryl urea. This paper investigates the reaction kinetics and the influence of electron withdrawing/donating substituents on the reaction of N-carbamoylimidazoles with aniline. The overall reaction mechanism involves two zwitterionic intermediates, formed during dissociation and upon reaction of the liberated isocyanate with aniline. The rate limiting step for the reaction is a base catalysed proton transfer from the second zwitterionic intermediate. Although electron withdrawing substituents on the aryl group hinder dissociation, they significantly increase reaction rates compared to compounds bearing electron donating substituents. The imidazole liberated upon dissociation catalyses the rate determining step so that reactions of dissociated N-carbamoylimidazoles proceed more rapidly than those involving only isocyanates. In addition, the imidazole eliminates the need for anhydrous reaction conditions. The N-carbamoylimidazole methodology was demonstrated by preparing sorafenib, a biaryl urea kinase inhibitor, in good yield and excellent purity.

DIARYL UREAS AS CB1 ANTAGONISTS

Compounds of Formula I are provided. In which the variables are as described herein. Such compounds may be used to modulate CB1 activity in vivo or in vitro, and are particularly useful in the treatment of conditions responsive to CB1 modulation in humans, domesticated companion animals and livestock animals, including appetite disorders, obesity and addictive disorders. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies and various in vitro assays.